DNA minor groove binders: Back in the groove

Cancer Treatment Reviews

Volumn 35, Issue 5, 2009, Pages 437-450

  Cai, Xuemei ^a   Gray Jr , Phillip J ^b   Von Hoff, Daniel D ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

Alkylators; Brostallicin; Irofulven; Minor groove; Trabectidin

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; ADOZELESIN; ANTINEOPLASTIC AGENT; AZACITIDINE; BIZELESIN; BROSTALLICIN; CAPECITABINE; CARZELESIN; CISPLATIN; DIMINAZENE ACETURATE; DISTAMYCIN A; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; IROFULVEN; MELPHALAN; PENTAMIDINE; PIBROZELESIN; PNU 145156E; PNU 151807; RACHELMYCIN; STILBAMIDINE; TALLIMUSTINE; TRABECTEDIN; UNCLASSIFIED DRUG;

ACTINOMYCOSIS; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLASTOMYCOSIS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BONE PAIN; BREAST CANCER; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHILDHOOD CANCER; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; EWING SARCOMA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL STROMAL TUMOR; GRANULOCYTOPENIA; HEAD AND NECK CANCER; HEPATOBLASTOMA; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LEIOMYOSARCOMA; LEISHMANIASIS; LIPOSARCOMA; LIVER CELL CARCINOMA; LIVER TOXICITY; LUNG EDEMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MALIGNANT MESOTHELIOMA; MAXIMUM TOLERATED DOSE; MELANOMA; MENTAL DISEASE; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEPHROBLASTOMA; NEPHROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PANCREAS CANCER; PANCYTOPENIA; PNEUMOCYSTIS PNEUMONIA; PROSTATE CANCER; PROTEIN DNA INTERACTION; RECOMMENDED DRUG DOSE; RETINA DISEASE; REVIEW; RHABDOMYOLYSIS; RHABDOMYOSARCOMA; SARCOMA; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMACH CANCER; SURVIVAL RATE; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TRYPANOSOMIASIS; VISUAL DISORDER; VISUAL IMPAIRMENT; VOMITING;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DNA; HUMANS; MOLECULAR CONFORMATION; NEOPLASMS;

EID: 68049118844     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.02.004     Document Type: Review

References (97)

1. Woynarowska B.A., and Woynarowski J.M. Preferential targeting of apoptosis in tumor versus normal cells. Biochim Biophys Acta 1587 2-3 (2002) 309-317 [July 18]
2. Baraldi P.G., Bovero A., Fruttarolo F., et al. DNA minor groove binders as potential antitumor and antimicrobial agents. Med Res Rev 24 4 (2004) 475-528 [July]
3. Wilson W.D., Nguyen B., Tanious F.A., et al. Dications that target the DNA minor groove: compound design and preparation, DNA interactions, cellular distribution and biological activity. Curr Med Chem 5 4 (2005) 389-408 [July]
4. Pathak M.K., Dhawan D., Lindner D.J., Borden E.C., Farver C., and Yi T. Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Mol Cancer Ther 1 14 (2002) 1255-1264 [December]
5. Stephens B., Han H., Hostetter G., Demeure M.J., and Von Hoff D.D. Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells. Mol Cancer Ther 7 1 (2008) 202-210 [January]
6. Reddy B.S., Sharma S.K., and Lown J.W. Recent developments in sequence selective minor groove DNA effectors. Curr Med Chem 8 5 (2001) 475-508 [April]
7. Hurley L.H., Reynolds V.L., Swenson D.H., Petzold G.L., and Scahill T.A. Reaction of the antitumor antibiotic CC-1065 with DNA: structure of a DNA adduct with DNA sequence-specificity. Science 226 4676 (1984) 843-844 [New York, NY, November 16]
8. Broggini M., Erba E., Ponti M., et al. Selective DNA interaction of the novel distamycin derivative FCE 24517. Cancer Res 51 1 (1991) 199-204 [January 1]
9. Colella G., Marchini S., D'Incalci M., Brown R., and Broggini M. Mismatch repair-deficiency is associated with resistance to DNA minor groove alkylating agents. Brit J Cancer 80 3-4 (1999) 338-343 [May]
10. Susbielle G., Blattes R., Brevet V., Monod C., and Kas E. Target practice: aiming at satellite repeats with DNA minor groove binders. Curr Med Chem 5 4 (2005) 409-420 [July]
11. Arcamone F., Penco S., Orezzi P., Nicolella V., and Pirelli A. Structure and synthesis of distamycin A. Nature 203 (1964) 1064-1065 [September 5]
12. Pelton J.G., and Wemmer D.E. Structural modeling of the distamycin A-d(CGCGAATTCGCG)2 complex using 2D NMR and molecular mechanics. Biochemistry 27 21 (1988) 8088-8096 [October 18]
13. Baguley B.C. Nonintercalative DNA-binding antitumour compounds. Mol Cell Biochem 43 3 (1982) 167-181 [April 2]
14. Herzig M.C., Trevino A.V., Arnett B., and Woynarowski J.M. Tallimustine lesions in cellular DNA are AT sequence-specific but not region-specific. Biochemistry 38 42 (1999) 14045-14055 [October 19]
15. Erba E., Mascellani E., Pifferi A., and D'Incalci M. Comparison of cell-cycle phase perturbations induced by the DNA minor groove alkylator tallimustine and by melphalan in the SW626 cell line. Int J Cancer 62 2 (1995) 170-175 [July 17]
16. Rossi R., Montecucco A., Capolongo L., et al. The alkylating antitumor drug tallimustine does not induce DNA repair. Anticancer Res 16 6B (1996) 3779-3783 [November-December]
17. Agen C., Sironi A.M., Danesi R., et al. Characterization of the toxicity of distamycin derivatives on cancer cell lines and rat heart. Toxicology 75 3 (1992) 209-219 [November 15]
18. Volpe D.A., Du D.L., Zurlo M.G., Mongelli N., and Murphy M.J. Comparative in vitro myelotoxicity of FCE 24517, a distamycin derivative, to human, canine and murine hematopoietic progenitor cells. Invest New Drugs 10 4 (1992) 255-261 [November]
19. Sessa C., Pagani O., Zurlo M.G., et al. Phase I study of the novel distamycin derivative tallimustine (FCE 24517). Ann Oncol 5 10 (1994) 901-907 [December]
20. Weiss G.R., Poggesi I., Rocchetti M., et al. A phase I and pharmacokinetic study of tallimustine [PNU-152241 (FCE 24517)] in patients with advanced cancer. Clin Cancer Res 4 1 (1998) 53-59 [January]
21. Beran M., Jeha S., O'Brien S., et al. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study. Clin Cancer Res 3 12 Pt 1 (1997) 2377-2384 [December]
22. Ciomei M., Pastori W., Mariani M., Sola F., Grandi M., and Mongelli N. New sulfonated distamycin A derivatives with bFGF complexing activity. Biochem Pharmacol 47 2 (1994) 295-302 [January 20]
23. Sola F., Capolongo L., Moneta D., Ubezio P., and Grandi M. The antitumor efficacy of cytotoxic drugs is potentiated by treatment with PNU-145156E, a growth-factor-complexing molecule. Cancer Chemother Pharmacol 43 3 (1999) 241-246
24. Sola F., Farao M., Pesenti E., Marsiglio A., Mongelli N., and Grandi M. Antitumor activity of FCE 26644 a new growth-factor-complexing molecule. Cancer Chemother Pharmacol 36 3 (1995) 217-222
25. Marchini S., Ciro M., Gallinari F., et al. Alpha-bromoacryloyl derivative of distamycin A (PNU-151807): a new non-covalent minor groove DNA binder with antineoplastic activity. Brit J Cancer 80 7 (1999) 991-997 [June]
26. Cozzi P., Beria I., Caldarelli M., Geroni C., Mongelli N., and Pennella G. Cytotoxic alpha-bromoacrylic derivatives of distamycin analogues modified at the amidino moiety. Bioorgan Med Chem Lett 10 11 (2000) 1273-1276 [June 5]
27. Geroni C., Marchini S., Cozzi P., et al. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione. Cancer Res 62 8 (2002) 2332-2336 [April 15]
28. Fedier A., Fowst C., Tursi J., et al. Brostallicin (PNU-166196) - a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells. Brit J Cancer 89 8 (2003) 1559-1565 [October 20]
29. Ten Tije A.J., Verweij J., Sparreboom A., et al. Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer. Clin Cancer Res 9 8 (2003) 2957-2964 [August 1]
30. Lockhart A.C., Howard M., Hande K.R., et al. A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors. Clin Cancer Res 10 2 (2004) 468-475 [January 15]
31. Broggini M., Marchini S., Fontana E., Moneta D., Fowst C., and Geroni C. Brostallicin: a new concept in minor groove DNA binder development. Anti-Cancer Drugs 15 1 (2004) 1-6 [January]
32. Leahy M., Ray-Coquard I., Verweij J., et al. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Eur J Cancer 43 2 (2007) 308-315 [January]
33. Sabatino M.A., Colombo T., Geroni C., Marchini S., and Broggini M. Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove binder, brostallicin. Clin Cancer Res 9 14 (2003) 5402-5408 [November 1]
34. Lorusso FZ D., Scalone S., Secomandi R., Ferrandina G., Scambia G., Jannuzzo M.G., Petroccione A., Comis S., and Raspagliesi F. Phase II exploratory study of brostallicin in patients with ovarian cancer resistant/refractory to platinum-based chemotherapy. J Clin Oncol 26 Suppl. (2008) [May 20; abstract 16520]
35. Hanka L.J., Dietz A., Gerpheide S.A., Kuentzel S.L., and Martin D.G. CC-1065 (NSC-298223), a new antitumor antibiotic. Production, in vitro biological activity, microbiological assays and taxonomy of the producing microorganism. J Antibiot 31 12 (1978) 1211-1217 [December]
36. Li L.H., Swenson D.H., Schpok S.L., Kuentzel S.L., Dayton B.D., and Krueger W.C. CC-1065 (NSC 298223), a novel antitumor agent that interacts strongly with double-stranded DNA. Cancer Res 42 3 (1982) 999-1004 [March]
37. Bhuyan B.K., Newell K.A., Crampton S.L., and Von Hoff D.D. CC-1065 (NSC 298223), a most potent antitumor agent: kinetics of inhibition of growth, DNA synthesis, and cell survival. Cancer Res 42 9 (1982) 3532-3537 [September]
38. Aaron C.S., Sorg R., and Zimmer D. The mouse bone marrow micronucleus test: evaluation of 21 drug candidates. Mutat Res 223 2 (1989) 129-140 [June]
39. Li L.H., Kelly R.C., Warpehoski M.A., McGovren J.P., Gebhard I., and DeKoning T.F. Adozelesin, a selected lead among cyclopropylpyrroloindole analogs of the DNA binding antibiotic, CC-1065. Investi New Drugs 9 2 (1991) 137-148 [May]
40. Bhuyan B.K., Smith K.S., Adams E.G., Wallace T.L., Von Hoff D.D., and Li L.H. Adozelesin, a potent new alkylating agent: cell-killing kinetics and cell-cycle effects. Cancer Chemother Pharmacol 30 5 (1992) 348-354
41. Bhuyan B.K., Smith K.S., Adams E.G., Petzold G.L., and McGovren J.P. Lethality, DNA alkylation, and cell-cycle effects of adozelesin (U-73975) on rodent and human cells. Cancer Res 52 20 (1992) 5687-5692 [October 15]
42. Smith K.S., Folz B.A., Adams E.G., and Bhuyan B.K. Synergistic and additive combinations of several antitumor drugs and other agents with the potent alkylating agent adozelesin. Cancer Chemother Pharmacol 35 6 (1995) 471-482
43. Cote S., and Momparler R.L. Evaluation of the antineoplastic activity of adozelesin alone and in combination with 5-aza-2′-deoxycytidine and cytosine arabinoside on DLD-1 human colon carcinoma cells. Anti-Cancer Drugs 4 3 (1993) 327-333 [June]
44. Burris H., Earhart R., Kuhn J., et al. A phase I trial of adozelesin. A novel DNA sequence-specific alkylating agent. Proc Am Assoc Cancer Res 33 (1992) 520
45. Shamdas G.J., Alberts D.S., Modiano M., et al. Phase I study of adozelesin (U-73,975) in patients with solid tumors. Anti-Cancer Drugs 5 1 (1994) 10-14 [February]
46. Fleming G.F., Ratain M.J., O'Brien S.M., et al. Phase I study of adozelesin administered by 24 h continuous intravenous infusion. J Natl Cancer Inst 86 5 (1994) 368-372 [March 2]
47. Foster B.J., LoRusso P.M., Poplin E., et al. Phase I trial of adozelesin using the treatment schedule of daily x5 every 3 weeks. Invest New Drugs 13 4 (1996) 321-326
48. Burris H.A., Dieras V.C., Tunca M., et al. Phase I study with the DNA sequence-specific agent adozelesin. Anti-Cancer Drugs 8 6 (1997) 588-596 [July]
49. Cristofanilli M., Bryan W.J., Miller L.L., et al. Phase II study of adozelesin in untreated metastatic breast cancer. Anti-Cancer Drugs 9 9 (1998) 779-782 Oct
50. Woynarowski J.M., Krugliak M., and Ginsburg H. Pharmacogenomic analyses of targeting the AT-rich malaria parasite genome with AT-specific alkylating drugs. Mol Biochem Parasitol 154 1 (2007) 70-81 [July]
51. Li L.H., DeKoning T.F., Kelly R.C., et al. Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue. Cancer Res 52 18 (1992) 4904-4913 [September 15]
52. Houghton P.J., Cheshire P.J., Hallman II J.D., and Houghton J.A. Therapeutic efficacy of the cyclopropylpyrroloindole, carzelesin, against xenografts derived from adult and childhood solid tumors. Cancer Chemoth Pharmacol 36 1 (1995) 45-52
53. Wolff I., Bench K., Beijnen J.H., et al. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days. Clin Cancer Res 2 10 (1996) 1717-1723 [October]
54. Awada A., Punt C.J., Piccart M.J., et al. Phase I study of carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule. Brit J Cancer 79 9-10 (1999) 1454-1461 [March]
55. van Tellingen O., Punt C.J., Awada A., et al. A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study. Cancer Chemother Pharmacol 41 5 (1998) 377-384
56. van Tellingen O., Nooijen W.J., Schaaf L.J., et al. Comparative pharmacology of the novel cyclopropylpyrroloindole-prodrug carzelesin in mice, rats, and humans. Cancer Res 58 11 (1998) 2410-2416 [June 1]
57. Pavlidis N., Aamdal S., Awada A., et al. Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG). Cancer Chemother Pharmacol 46 2 (2000) 167-171
58. Ding Z.M., and Hurley L.H. DNA interstrand cross-linking, DNA sequence-specificity, and induced conformational changes produced by a dimeric analog of (+)-CC-1065. Anti-Cancer Drug Design 6 5 (1991) 427-452 [November]
59. Carter C.A., Waud W.R., Li L.H., DeKoning T.F., McGovren J.P., and Plowman J. Preclinical antitumor activity of bizelesin in mice. Clin Cancer Res 2 7 (1996) 1143-1149 [July]
60. Volpe D.A., Tomaszewski J.E., Parchment R.E., et al. Myelotoxic effects of the bifunctional alkylating agent bizelesin on human, canine and murine myeloid progenitor cells. Cancer Chemother Pharmacol 39 1-2 (1996) 143-149
61. Pitot H.C., Reid J.M., Sloan J.A., et al. A phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors. Clin Cancer Res 8 3 (2002) 712-717 [March]
62. Schwartz G.H., Patnaik A., Hammond L.A., et al. A phase I study of bizelesin, a highly potent and selective DNA interactive agent, in patients with advanced solid malignancies. Ann Oncol 14 5 (2003) 775-782 [May]
63. Yasuzawa T., Iida T., Muroi K., Ichimura M., Takahashi K., and Sano H. Structures of duocarmycins, novel antitumor antibiotics produced by Streptomyces sp. Chem Pharm Bull 36 9 (1988) 3728-3731 [September]
64. Gomi K., Kobayashi E., Miyoshi K., et al. Anticellular and antitumor activity of duocarmycins, novel antitumor antibiotics. Jpn J Cancer Res 83 1 (1992) 113-120 [January]
65. Ogasawara H., Nishio K., Takeda Y., et al. A novel antitumor antibiotic, KW-2189 is activated by carboxyl esterase and induces DNA strand breaks in human small cell lung cancer cells. Jpn J Cancer Res 85 4 (1994) 418-425 [April]
66. Kobayashi E., Okamoto A., Asada M., et al. Characteristics of antitumor activity of KW-2189, a novel water-soluble derivative of duocarmycin, against murine and human tumors. Cancer Res 54 9 (1994) 2404-2410 [May 1]
67. Alberts S.R., Erlichman C., Reid J.M., et al. Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks. Clin Cancer Res 4 9 (1998) 2111-2117 [September]
68. Niitani H., Horikoshi N., Hasegawa K., Fukuoka M., Kudoh S., and Hino M. Phase I study of KW-2189, a derivative of new anticancer antibiotic duocarmycin. Proc Am Assoc Cancer Res 36 (1995) A1446
69. Abbruzzese J., Madden T., and Newman R. Phase I clinical and pharmacokinetic trial of KW2189 in patients with solid tumors. Proc Am Assoc Cancer Res 37 (1996) 1138
70. Small E.J., Figlin R., Petrylak D., et al. A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma. Invest New Drugs 18 2 (2000) 193-197 [May]
71. Markovic S.N., Suman V.J., Vukov A.M., et al. Phase II trial of KW2189 in patients with advanced malignant melanoma. Am J Clin Oncol 25 3 (2002) 308-312 [June]
72. McMorris T.C., Kelner M.J., Wang W., Yu J., Estes L.A., and Taetle R. (Hydroxymethyl)acylfulvene: an illudin derivative with superior antitumor properties. J Nat Prod 59 9 (1996) 896-899 [September]
73. Kelner M.J., McMorris T.C., Estes L., Wang W., Samson K.M., and Taetle R. Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents. Invest New Drugs 14 2 (1996) 161-167
74. Kelner M.J., McMorris T.C., Estes L., Samson K.M., Trani N.A., and MacDonald J.R. Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan. Leukemia 14 1 (2000) 136-141 [January]
75. Britten C.D., Hilsenbeck S.G., Eckhardt S.G., et al. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model. Cancer Res 59 5 (1999) 1049-1053 [March 1]
76. Woynarowska B.A., Roberts K., Woynarowski J.M., MacDonald J.R., and Herman T.S. Targeting apoptosis by hydroxymethylacylfulvene in combination with gamma radiation in prostate tumor cells. Radiat Res 154 4 (2000) 429-438 [October]
77. Dick R.A., Yu X., and Kensler T.W. NADPH alkenal/one oxidoreductase activity determines sensitivity of cancer cells to the chemotherapeutic alkylating agent irofulven. Clin Cancer Res 10 4 (2004) 1492-1499 [February 15]
78. Lee M.S., Gupta N., Penson R.T., et al. Cone damage in patients receiving high-dose irofulven treatment. Arch Ophthalmol 123 1 (2005) 29-34 [January]
79. Sakai R., Rinehart K.L., Guan Y., and Wang A.H. Additional antitumor ecteinascidins from a Caribbean tunicate: crystal structures and activities in vivo. Proc Natl Acad Sci United States Am 89 23 (1992) 11456-11460 [December 1]
80. Tavecchio M., Simone M., Erba E., et al. Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer 44 4 (2008) 609-618 [March]
81. Jin S., Gorfajn B., Faircloth G., and Scotto K.W. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci United States Am 97 12 (2000) 6775-6779 [June 6]
82. Pommier Y., Kohlhagen G., Bailly C., Waring M., Mazumder A., and Kohn K.W. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin-743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 35 41 (1996) 13303-13309 [October 15]
83. Moore B.M., Seaman F.C., and Hurley L.H. NMR-based model of an ecteinascidin-743-DNA adduct. J Am Chem Soc 119 23 (1997) 5475-5476
84. Erba E., Cavallaro E., Damia G., et al. The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring. Oncol Res 14 11-12 (2004) 579-587
85. Minuzzo M., Marchini S., Broggini M., Faircloth G., D'Incalci M., and Mantovani R. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci United States Am 97 12 (2000) 6780-6784 [June 6]
86. Damia G., Silvestri S., Carrassa L., et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA repair pathways. Int J Cancer 92 4 (2001) 583-588 [May 15]
87. Carter N.J., and Keam S.J. Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 67 15 (2007) 2257-2276 [May 15]
88. Trabectedin: ecteinascidin-743, ecteinascidin-743, ET 743, ET-743, NSC 684766. Drugs R&D 2006; 7(5): 317-328.
89. Lee J.K., Leslie E.M., Zamek-Gliszczynski M.J., and Brouwer K.L. Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity. Toxicol Appl Pharmacol 228 1 (2008) 17-23 [April 1]
90. Grosso F., Jones R.L., Demetri G.D., et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 8 7 (2007) 595-602 [July]
91. Martinez N., Sanchez-Beato M., Carnero A., et al. Transcriptional signature of ecteinascidin-743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol Cancer Ther 4 5 (2005) 814-823 [May]
92. Baraldi P.G., Preti D., Fruttarolo F., Tabrizi M.A., and Romagnoli R. Hybrid molecules between distamycin A and active moieties of antitumor agents. Bioorg Med Chem 15 1 (2007) 17-35 [January 1]
93. Baraldi P.G., Beria I., Cozzi P., et al. Cinnamoyl nitrogen mustard derivatives of pyrazole analogues of tallimustine modified at the amidino moiety: design, synthesis, molecular modeling and antitumor activity studies. Bioorg Med Chem 12 14 (2004) 3911-3921 [July 15]
94. Groen H.J., de Vries E.G., Wynendaele W., et al. PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: a phase I and pharmacokinetic study. Clin Cancer Res 7 12 (2001) 3928-3933 [December]
95. Tichenor M.S., MacMillan K.S., Stover J.S., et al. Rational design, synthesis, and evaluation of key analogues of CC-1065 and the duocarmycins. J Am Chem Soc 129 45 (2007) 14092-14099 [November 14]
96. Boger D.L., Boyce C.W., Garbaccio R.M., and Goldberg J.A. CC-1065 and the duocarmycins: synthetic studies. Chem Rev 97 3 (1997) 787-828 [May 8]
97. Alberts S.R., Suman V.J., Pitot H.C., Camoriano J.K., and Rubin J. Use of KW-2189, a DNA minor groove binding agent, in patients with hepatocellular carcinoma: a North Central Cancer Treatment Group (NCCTG) phase II clinical trial. Int J Gastrointest Cancer (2008) [January 3]